Asteria Health recalled 1,699 sterile estradiol pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately and contact their healthcare provider for advice. The recall affects pellets distributed nationwide in the USA.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Estradiol pellets are commonly used in hormone replacement therapy to alleviate symptoms of menopause and other hormonal imbalances. Consumers typically purchase these pellets for their effectiveness in hormone regulation.
The potential presence of metal particulate matter in the estradiol pellets can lead to serious health issues if ingested, causing internal damage or other complications.
This recall is not part of a broader industry pattern.
Consumers face potential health risks if they continue to use the affected estradiol pellets. Immediate cessation of use is necessary to avoid possible health complications.
The lot number and expiration date can typically be found on the packaging of the estradiol pellets.
Refund processing may take 4-6 weeks after the request is submitted.
Keep receipts, correspondence with the company, and photographs of the product as documentation for your records.
The recall includes estradiol pellets, 18 mg, Lot#: 253000123, with an expiration date of June 2, 2026. The product is distributed by Asteria Health, located at 432 Industrial Ln, Birmingham, AL 3521.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Asteria Health recalled 133 estradiol pellets on January 26, 2026, after detecting potential metal particulate matter. The recall, classified as Class II, affects pellets with lot number 253000126 and an expiration date of June 9, 2026. Consumers must stop using the product immediately and contact their healthcare provider for guidance.
Asteria Health recalled 60,868 testosterone pellets on January 26, 2026, due to contamination risks. The recall affects specific lots of the product that may contain metal particulate matter. Consumers must stop using the product immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,015 testosterone pellets on January 26, 2026 due to potential metal particulate contamination. The recall affects products distributed nationwide in the United States. Consumers must stop using the pellets immediately and contact their healthcare provider for guidance.
Asteria Health recalled 89,074 testosterone pellets on January 26, 2026. The recall stems from potential metal particulate contamination. Consumers must stop using the product and contact their healthcare provider immediately.
Asteria Health recalled 22,478 Estradiol 12.5 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The FDA classified this recall as Class II, indicating a high hazard level.
Asteria Health recalled 24,099 Estradiol, 10 mg pellets on January 26, 2026, due to potential metal particulate contamination. Consumers should stop using the product immediately. The recall affects pellets distributed nationwide in the USA.
Asteria Health recalled 50,990 Estradiol pellets on January 26, 2026, due to potential metal particulate matter contamination. The recall affects products distributed nationwide in the USA. Consumers should stop using the pellets immediately and seek guidance from healthcare providers.
Asteria Health recalled 1,464 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects products distributed nationwide. Consumers must stop using the product immediately and seek guidance from healthcare providers.